Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

51.9%

14 terminated/withdrawn out of 27 trials

Success Rate

41.7%

-44.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

2 recruiting14 withdrawn

Enrollment Performance

Analytics

Phase 1
16(69.6%)
N/A
4(17.4%)
Phase 2
2(8.7%)
Early Phase 1
1(4.3%)
23Total
Phase 1(16)
N/A(4)
Phase 2(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT04767841Phase 1Withdrawn

The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis

Role: lead

NCT04789837Phase 1Withdrawn

The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis

Role: lead

NCT04344678Not ApplicableWithdrawn

The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Role: lead

NCT04761848Phase 1Withdrawn

Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

Role: lead

NCT05030623Phase 1Withdrawn

The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Role: lead

NCT05058417Phase 2Withdrawn

Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis

Role: lead

NCT04757571Phase 1Withdrawn

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

Role: lead

NCT04410341Phase 1Withdrawn

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Role: lead

NCT04751071Phase 1Withdrawn

The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Role: lead

NCT04068246Phase 1Completed

The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

Role: lead

NCT04761861Phase 2Withdrawn

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Role: lead

NCT05453916Phase 1Withdrawn

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Role: lead

NCT06546111Phase 1Recruiting

Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection

Role: lead

NCT06302049Phase 1Recruiting

Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis

Role: lead

NCT04075110Early Phase 1Completed

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

Role: lead

NCT04433988Phase 1Withdrawn

Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients

Role: lead

NCT05433402Phase 1Withdrawn

Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Role: lead

NCT04094207Phase 1Completed

Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

Role: lead

NCT05047146Completed

The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt

Role: lead

NCT04069819Not ApplicableCompleted

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Role: lead